Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Omeros Corporation (NASDAQ:OMER) stock surged over 160% following an agreement where Novo Nordisk (NYSE:NVO) acquired exclusive global rights to Omeros' candidate drug zaltenibart, targeting rare blood and kidney disorders, including positive Phase 2 data for paroxysmal nocturnal hemoglobinuria (PNH). The deal provides Omeros with $340 million in upfront and near-term payments, up to $2.1 billion in potential milestones, and tiered royalties, as Novo Nordisk plans to initiate a global Phase 3 program for the asset. This transaction underscores the significant value placed on advanced rare disease therapies within the pharmaceutical M&A landscape.

Analysis

The asset purchase and license agreement between Omeros Corporation (NASDAQ:OMER) and Novo Nordisk A/S (NYSE:NVO) for the candidate drug zaltenibart has profoundly impacted Omeros, driving its stock up 163.77% to $10.81 on Wednesday, with session volume surging to 89.21 million shares. Under the terms, Omeros will receive $340 million in upfront and near-term milestone payments, with potential for up to $2.1 billion in total milestones plus tiered royalties for zaltenibart, which has shown positive Phase 2 data in paroxysmal nocturnal hemoglobinuria (PNH).

This agreement significantly de-risks Omeros' financial position and validates its MASP-3 inhibitor platform, providing substantial non-dilutive capital for further development of its remaining preclinical MASP-3 programs. Novo Nordisk gains exclusive global rights to a late-stage asset targeting rare blood and kidney disorders, with plans to initiate a global Phase 3 program for zaltenibart in PNH, bolstering its rare disease pipeline.

Novo Nordisk's stock, however, saw a modest 0.32% increase, potentially overshadowed by the concurrent news of US layoffs across various departments, including rare diseases, human resources, and clinical development. This suggests a broader strategic review or cost-cutting initiative within Novo Nordisk, even as it expands its rare disease portfolio through acquisition. The transaction is expected to close in Q4 2025.

Key Decisions for Investors

• Investors in OMER should evaluate the sustainability of the current rally against future milestone dependencies and the long closing period for the transaction.
• Investors in NVO should consider the strategic implications of acquiring a promising rare disease asset while simultaneously undergoing significant layoffs, potentially signaling a re-prioritization of internal R&D or cost efficiencies.
• Monitor the progress of zaltenibart's Phase 3 trials and the successful closure of the transaction in Q4 2025 as key catalysts for both companies.